BMS-986408
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BMS-986408, covering 2025-10-03 to 2025-10-03. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors [Phase 1, Phase 2]